Scroll to top

News

CLINUVEL
Posted by CLINUVEL
February 13, 2016

CLINUVEL brief on European commercialisation

19 February 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
February 10, 2016

SCENESSE® receives US FDA orphan designation for cutaneous porphyrias

10 February 2016 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
February 7, 2016

Presentation to international porphyria patient group

8 February 2016 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
January 28, 2016

Appendix 4C - Q2 FY16

28 January 2016 Enclosed is a copy of the Quarterly report for...

Read More
CLINUVEL
Posted by CLINUVEL
January 25, 2016

Form 604

25 January 2016 Enclosed is a notice of a change of interest...

Read More
We use cookies to give you the best experience.